Cancer cure hope as UK patients trial world’s first personalised mRNA vaccine for melanoma
The world’s first personalised mRNA cancer jab for melanoma – which also has the potential to stop lung, bladder and kidney cancer – is being tested in British patients.
The “gamechanger” jab, which offers hope of a cure, is custom-built for each person in just a few weeks.
It works by telling the body to hunt down cancer cells and prevent the deadly disease from coming back.
A stage 2 trial of the jab, involving pharma firms Moderna and MSD, found it dramatically reduced the risk of the cancer returning in melanoma patients.
Now a final phase 3 trial has been launched, led by University College London Hospitals NHS Foundation Trust (UCLH).
Dr Heather Shaw, national co-ordinating investigator for
